Global Insomnia Market Size, Share and Trends Analysis Report – Industry Overview and Forecast to 2032

Insomnia Market Size

• The global insomnia market size was valued at USD 5.84 billion in 2024 and is expected to reach USD 8.89 billion by 2032, at a CAGR of 5.40% during the forecast period
• The market growth is primarily driven by the increasing prevalence of sleep disorders, rising awareness about the impact of poor sleep on health, and growing adoption of medical interventions for insomnia
• Furthermore, the expansion of healthcare infrastructure, the availability of prescription and over-the-counter treatment options, and rising investment in sleep research are accelerating the demand for insomnia solutions

Insomnia Market Analysis

• The Insomnia market, encompassing therapeutic solutions and interventions for sleep disorders, is increasingly gaining attention due to rising prevalence rates, growing awareness about sleep health, and expanding healthcare infrastructure globally
• The escalating demand for insomnia treatments is primarily fueled by lifestyle changes, increased stress levels, aging populations, and a higher incidence of comorbid conditions such as anxiety and depression
• North America dominated the insomnia market with the largest revenue share of 41.5% in 2024, supported by advanced healthcare infrastructure, high treatment adoption rates, and the presence of leading pharmaceutical and medical device companies, with the U.S. experiencing substantial growth due to higher prevalence rates, robust clinical trial activity, and favorable reimbursement policies
• Asia-Pacific is expected to be the fastest-growing region in the insomnia market during the forecast period, driven by increasing urbanization, rising disposable incomes, growing awareness of sleep disorders, and expanding access to healthcare in countries such as China, India, and Japan
• The oral segment dominated the insomnia market with the largest market revenue share of 71.6% in 2024, attributed to ease of administration, high patient compliance, and the availability of multiple dosage forms such as tablets, capsules, and liquid formulations

Report Scope and Insomnia Market Segmentation   

Insomnia Market Trends

Rising Demand for Personalized and Technology-Driven Sleep Solutions

• A significant and accelerating trend in the global insomnia market is the growing adoption of technology-enabled and personalized sleep management solutions. This includes digital therapeutics, wearable sleep monitors, and mobile applications that help track sleep patterns, deliver cognitive behavioral therapy for insomnia (CBT-I), and provide tailored recommendations for improved sleep quality
  • For instance, in 2024, several mobile health platforms expanded their insomnia-focused offerings, incorporating real-time sleep tracking and interactive guidance to help users manage sleep disturbances more effectively. These initiatives are expected to drive the adoption of insomnia therapies across both clinical and homecare settings
• Integration with digital platforms enables patients and healthcare providers to monitor treatment efficacy, adherence, and behavioral improvements, creating a more interactive and informed care experience. The combination of behavioral, pharmacological, and device-assisted interventions is increasing treatment success rates and patient satisfaction
• The use of technology also allows for remote consultations, telemedicine support, and continuous monitoring, enhancing accessibility to sleep care services for populations in urban and rural regions alike
• This trend towards more personalized, accessible, and evidence-based sleep solutions is fundamentally reshaping patient expectations in insomnia management. Consequently, pharmaceutical companies, digital health startups, and clinical providers are increasingly investing in solutions that combine medical therapy with technology-assisted monitoring and intervention
• The demand for integrated, patient-centric insomnia management solutions is rising rapidly across both adult and elderly populations, as consumers and clinicians prioritize effective, convenient, and data-driven approaches to improving sleep health

Insomnia Market Dynamics

Driver

Growing Need Due to Rising Prevalence of Sleep Disorders and Awareness

• The increasing prevalence of insomnia and related sleep disorders among adults and elderly populations, coupled with rising awareness about the importance of quality sleep, is a significant driver for the heightened demand for effective insomnia treatments
  • For instance, in 2024, healthcare providers and digital health platforms expanded initiatives focused on sleep health education, emphasizing the benefits of behavioral therapy, cognitive interventions, and pharmacological management. Such strategies by key companies are expected to drive the Insomnia industry growth in the forecast period
• As patients become more aware of the health consequences of poor sleep, there is growing demand for advanced and accessible treatment options, including prescription medications, cognitive behavioral therapy for insomnia (CBT-I), and integrated therapeutic programs that combine behavioral and pharmacological approaches
• Furthermore, increasing research into novel treatment modalities and growing investment by pharmaceutical companies in R&D are fostering the development of more effective and targeted therapies for insomnia
• The convenience of home-based therapy options, telemedicine consultations, and mobile health interventions are key factors propelling the adoption of insomnia treatments across both clinical and homecare settings. The trend toward patient-centric approaches and user-friendly digital solutions further contributes to market growth

Restraint/Challenge

Challenges Related to Treatment Costs, Side Effects, and Patient Compliance

• The relatively high cost of some advanced insomnia therapies, particularly new pharmacological formulations or personalized digital interventions, can be a barrier to adoption for price-sensitive consumers, especially in developing regions or among populations without comprehensive insurance coverage
• Side effects associated with certain medications, including daytime drowsiness, dependency risks, or interactions with other drugs, can limit patient compliance and hinder long-term treatment adherence
• Addressing these challenges through patient education, clinician-guided therapy plans, and the development of safer, more affordable treatment options is crucial for sustaining market growth
• In addition, a lack of awareness or reluctance to seek treatment due to stigma around sleep disorders may impede market penetration, requiring continued efforts in public health campaigns and physician advocacy
• Overcoming these barriers through increased accessibility, ongoing clinical research, and integrated treatment approaches that combine behavioral and pharmacological therapies will be vital for the sustained expansion of the Insomnia market
• Monitoring treatment outcomes and incorporating patient feedback into therapy plans enhances adherence and effectiveness, further driving confidence and adoption in both clinical and homecare environments

Insomnia Market Scope

The market is segmented on the basis of therapy type, drug class, route of administration, end-users, and distribution channel.

• By Therapy Type

On the basis of therapy type, the Insomnia market is segmented into non-pharmacological therapy and pharmacological therapy. The pharmacological therapy segment dominated the largest market revenue share of 52.5% in 2024, driven by the widespread use of prescription medications among patients with moderate to severe insomnia. Pharmacological interventions are preferred due to their rapid onset of action, consistent efficacy, and ability to improve both sleep duration and quality. The segment benefits from a robust pipeline of novel formulations targeting different neurological pathways, increasing adoption among physicians and patients alike. Furthermore, marketing initiatives, insurance coverage, and clinical guidelines supporting pharmacological management bolster its continued dominance. The market also sees strong demand from patients seeking immediate relief, particularly in urban and aging populations where insomnia prevalence is higher.

The non-pharmacological therapy segment is expected to witness the fastest CAGR of 7.8% from 2025 to 2032, fueled by rising awareness of behavioral interventions and cognitive therapies. Non-pharmacological options, including cognitive behavioral therapy for insomnia (CBT-I), mindfulness practices, sleep hygiene programs, and light therapy, are increasingly preferred for their long-term benefits without the risk of dependency or adverse effects. The adoption of digital therapeutics, mobile applications, and telehealth platforms has expanded access to these therapies, especially in homecare and outpatient settings. Growing government initiatives promoting mental wellness and educational campaigns highlighting the effectiveness of non-drug interventions further drive growth. This segment’s expansion is also supported by the integration of wearable devices that monitor sleep patterns and provide personalized recommendations, making therapy more convenient and tailored for individual patients.

• By Drug Class

On the basis of drug class, the Insomnia market is segmented into melatonin antagonists, antidepressants, benzodiazepines, non-benzodiazepines, and others. The non-benzodiazepines segment held the largest market revenue share of 45.3% in 2024, owing to their favorable safety profile, reduced risk of dependency, and proven effectiveness in promoting both sleep onset and sleep maintenance. These drugs are widely recommended by clinicians as a first-line treatment for chronic insomnia, enhancing their market penetration. Increased physician preference, positive patient experiences, and growing awareness about the risks of long-term benzodiazepine use contribute to the segment's dominance.

The melatonin antagonist segment is projected to register the fastest CAGR of 6.9% from 2025 to 2032, supported by rising research, development, and adoption of circadian rhythm-targeting therapies. Melatonin receptor modulators are particularly effective for patients experiencing sleep disturbances due to circadian misalignment, such as shift workers or older adults. Growing awareness among healthcare providers and patients regarding the benefits of these therapies, combined with the development of oral and sustained-release formulations, drives growth. This segment also benefits from increasing adoption in specialized sleep clinics and homecare settings, where personalized sleep management solutions are in high demand.

• By Route of Administration

On the basis of route of administration, the Insomnia market is segmented into oral, parenteral, and others. The oral segment accounted for the largest market revenue share of 71.6% in 2024, attributed to ease of administration, high patient compliance, and the availability of multiple dosage forms such as tablets, capsules, and liquid formulations. Oral administration is widely adopted across hospitals, specialty clinics, and homecare settings due to convenience, cost-effectiveness, and suitability for both acute and chronic insomnia management. The segment benefits from extensive distribution networks and strong physician preference, particularly in outpatient care.

The parenteral segment is expected to witness the fastest CAGR of 5.8% from 2025 to 2032, driven by the need for rapid and controlled therapeutic intervention in hospital and specialty care settings. Intravenous and subcutaneous formulations are often utilized in patients with severe insomnia or comorbid conditions requiring close monitoring. Increasing investments in hospital-based sleep centers and the growing prevalence of refractory insomnia cases contribute to the adoption of parenteral therapies. Enhanced awareness among clinicians about the benefits of targeted administration, along with technological advancements improving drug stability and delivery, further support growth in this segment.

• By End-Users

On the basis of end-users, the Insomnia market is segmented into hospitals, homecare, specialty clinics, and others. Hospitals dominated the market with a revenue share of 50.4% in 2024, owing to their comprehensive role in patient diagnosis, complex treatment management, and follow-up care. Hospitals often provide multidisciplinary care involving both pharmacological and non-pharmacological therapies, which strengthens their market share. The presence of integrated sleep centers, research programs, and access to a wide range of insomnia treatments makes hospitals the preferred choice for patients with moderate to severe conditions.

The homecare segment is projected to witness the fastest CAGR of 8.2% from 2025 to 2032, fueled by the increasing demand for convenient, personalized insomnia management at home. Rising awareness of telemedicine, mobile health applications, and wearable devices that track sleep patterns has expanded the feasibility of home-based treatment. Patients increasingly prefer homecare for privacy, cost savings, and flexibility, particularly in managing chronic or mild insomnia. Government initiatives promoting community healthcare and the availability of remote consultations further accelerate adoption in this segment.

• By Distribution Channel

On the basis of distribution channel, the Insomnia market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The retail pharmacy segment held the largest market revenue share of 47.8% in 2024, driven by its widespread availability, consumer trust, and accessibility for both prescription and over-the-counter insomnia medications. Retail pharmacies provide immediate access to a broad range of therapies and are supported by trained pharmacists who guide patients on proper usage and dosage.

The online pharmacy segment is expected to witness the fastest CAGR of 9.1% from 2025 to 2032, driven by the growth of e-commerce, home delivery services, and tele-prescription platforms. Convenience, competitive pricing, and the ability to discreetly purchase medications are key factors boosting adoption. Urbanization, increasing internet penetration, and consumer preference for digital shopping further accelerate the uptake of online pharmacy services. The segment benefits from technological advancements such as app-based order tracking, automated reminders, and integration with telehealth consultations, making it increasingly attractive for patients seeking effective insomnia management solutions.

Insomnia Market Regional Analysis

• North America dominated the insomnia market with the largest revenue share of 41.5% in 2024, supported by advanced healthcare infrastructure, high treatment adoption rates, and the presence of leading pharmaceutical and medical device companies
• The market experienced substantial growth due to higher prevalence rates of insomnia, robust clinical trial activity, and favorable reimbursement policies
• In addition, increasing awareness of sleep disorders, expanding specialty sleep clinics, and adoption of both pharmacological and non-pharmacological therapies are further driving market expansion

U.S. Insomnia Market Insight

The U.S. insomnia market captured the largest revenue share within North America in 2024, fueled by the availability of specialized sleep centers, increasing patient awareness, and early adoption of innovative therapies. Rising demand for personalized treatment plans, coupled with government support for healthcare initiatives, contributes to the market’s growth. Furthermore, strong R&D activities in neuropharmacology and sleep medicine are enhancing treatment options and improving patient outcomes.

Europe Insomnia Market Insight

The Europe insomnia market is projected to expand at a substantial CAGR throughout the forecast period, primarily driven by increasing awareness of sleep disorders, government support for healthcare programs, and rising prevalence of insomnia. Countries such as Germany, France, and the U.K. are witnessing significant growth due to the establishment of specialized sleep clinics, ongoing clinical research, and the adoption of novel pharmacological and non-pharmacological therapies. Improved healthcare infrastructure and access to innovative treatment options are further fueling market expansion across the region.

U.K. Insomnia Market Insight

The U.K. insomnia market is anticipated to grow at a noteworthy CAGR during the forecast period, driven by rising awareness of sleep health, higher adoption of modern therapies, and the presence of specialized sleep clinics. Increased patient focus on mental well-being and sleep quality, along with government initiatives to support sleep disorder management, are supporting market growth. Additionally, ongoing research and collaboration with healthcare institutions are enhancing treatment options for patients.

Germany Insomnia Market Insight

The Germany insomnia market is expected to expand at a considerable CAGR during the forecast period, fueled by rising prevalence of sleep disorders, increasing healthcare expenditure, and the demand for innovative treatments. The presence of advanced diagnostic facilities and specialized sleep therapy centers enables early diagnosis and effective treatment. Growth is further supported by government policies promoting mental health and sleep disorder awareness.

Asia-Pacific Insomnia Market Insight

The Asia-Pacific insomnia market is poised to grow at the fastest CAGR during the forecast period, driven by increasing urbanization, rising disposable incomes, growing awareness of sleep disorders, and expanding access to healthcare in countries such as China, India, and Japan. Rising patient population, increasing investments in healthcare infrastructure, and adoption of both pharmacological and non-pharmacological treatments are fueling market growth.

Japan Insomnia Market Insight

The Japan insomnia market is witnessing significant growth due to the country’s high awareness of sleep health, rising prevalence of insomnia, and increasing adoption of treatment options. Expansion of specialty sleep clinics and government initiatives promoting sleep disorder management further support market development. An aging population and growing focus on mental well-being are also contributing to increased demand for insomnia therapies.

China Insomnia Market Insight

The China insomnia market accounted for the largest revenue share in Asia-Pacific in 2024, attributed to the country’s expanding healthcare access, rising middle-class population, and increasing investment in healthcare infrastructure for sleep disorders. Rising awareness of sleep hygiene, coupled with growing prevalence of insomnia, is driving demand for both pharmacological and non-pharmacological treatments. The availability of specialized treatment centers and ongoing clinical research are further boosting market growth.

Insomnia Market Share

The Insomnia industry is primarily led by well-established companies, including:

• Takeda Pharmaceutical Company Limited (Japan)
• Dr. Reddy’s Laboratories Ltd. (India)
• Pfizer Inc. (U.S.)
• Endo International plc (Ireland)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Sun Pharmaceutical Industries Ltd. (India)
• Novartis AG (Switzerland)
• Lupin Ltd. (India)
• Cipla Inc. (India)
• Aurobindo Pharma Ltd. (India)
• Torrent Pharmaceuticals Ltd. (India)
• Merck & Co., Inc. (U.S.)
• Apotex Inc. (Canada)
• Zydus Group (India)

Latest Developments in Global Insomnia Market

• In January 2022, Idorsia, a biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) approved daridorexant (brand name: Quviviq) for the treatment of adult patients with insomnia characterized by difficulties with sleep onset and/or sleep maintenance. This approval marked a significant advancement in insomnia therapy as daridorexant is a dual orexin receptor antagonist, offering patients an alternative to traditional sleep medications
• In August 2024, Big Health, a digital therapeutics company, announced that it received FDA clearance for its digital insomnia therapeutic, SleepioRx, for the treatment of chronic insomnia in adults as an adjunct to usual care. The clearance allows patients to access an evidence-based, digital behavioral therapy designed to improve sleep patterns and reduce insomnia symptoms
• In October 2024, Avadel Pharmaceuticals disclosed that the U.S. FDA expanded the approval of its sleep disorder drug Lumryz to children aged 7 and older. Previously approved for adults in 2023, Lumryz treats narcolepsy symptoms, including excessive daytime sleepiness and cataplexy, making it one of the few options for pediatric patients with sleep disorders
• In May 2025, Eisai, a global pharmaceutical company, announced that its dual orexin receptor antagonist, lemborexant (brand name: Dayvigo), received approval in China for the treatment of adults with insomnia characterized by difficulties with sleep onset and/or sleep maintenance. This launch expanded Eisai’s footprint in the Asian insomnia therapeutics market

SKU-26988